ERBB2 and neoplasm: Patients in the low-risk category of ER+HER2– BC (n = 67), characterized by no lymph node involvement, low Ki67-ITH, high CD8+ density in the IZ tumor aspect, and low ID of CD8+ cell density, achieved 10-year survival probability of 100%.